Filing Overview
Registrant: Soaring Eagle Acquisition Corp., a Cayman Islands SPAC associated with the proposed Ginkgo Bioworks transaction. The filing date and earliest reported event date were May 13, 2021. This Form 8-K reports an accounting correction related to the SPAC’s warrants; it does not provide operating results for Ginkgo Bioworks.
Financial Metrics and Liquidity
- The filing does not provide revenue, profit, operating cash flow, margins, debt, or liquidity balances.
- The company stated that the warrant accounting correction consists solely of non-cash adjustments and will not affect liquidity or cash flows.
- The revised unaudited balance sheet as of February 26, 2021 was furnished as Exhibit 99.1, but the provided filing text does not include its numerical balances.
Material Change Versus Prior Reporting
- Soaring Eagle previously classified its public and private placement warrants as components of equity.
- Following the SEC staff’s April 12, 2021 statement on SPAC warrant accounting, the company determined that the warrants should instead be classified as derivative liabilities under ASC 815-40.
- The warrants must be measured at fair value, with subsequent changes in fair value recognized in earnings.
- The company revised its February 26, 2021 IPO balance sheet to reflect the liability classification. The filing does not provide the amount of the adjustment or its effect on earnings or total liabilities.
Outlook, Risks, and Unusual Items
- The primary unusual item is the correction of warrant classification and related fair-value accounting.
- Future changes in warrant fair value may create earnings volatility, although they are non-cash in nature.
- The filing provides no revenue guidance, operating outlook, management forecast, or discussion of Ginkgo Bioworks’ business performance.
- The filing states that the Regulation FD disclosure, including Exhibit 99.1, was furnished rather than filed and is not subject to Exchange Act Section 18 liability or incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 for the revised February 26, 2021 balance sheet and quantify the reclassification.
- Verify the fair-value methodology and recurring income-statement impact for the public and private placement warrants.
- Assess the potential earnings volatility from future warrant fair-value changes.
- Confirm the separate disclosures and financial statements of Ginkgo Bioworks for operating metrics, liquidity, debt, and transaction-related risks.